Swiss study sees no link between cancer drug prices and patient benefits
New research from the University of Zurich renews calls for more transparency in the way drug prices are determined as more high-priced cancer drugs come on the market.
This content was published on
4 minutes
Jessica covers the good, the bad, and the ugly when it comes to big global companies and their impact in Switzerland and abroad. She’s always looking for a Swiss connection with her native San Francisco and will happily discuss why her hometown has produced some of the greatest innovations but can’t seem to solve its housing crisis.
Prices for cancer drugs have risen steeply in the last few years, straining healthcare systems and triggering debate about how prices are set. According to a report by Swiss public television RTS, the price for reimbursement for cancer-fighting drugs in Switzerland has increased by 54% in the last five years.
In the studyExternal link published in the Lancet, researchers at the University of Zurich and Harvard Medical School have concluded that price has little to do with the effectiveness of a drug.
“Our study clearly shows that, in general, for Switzerland, Germany, England and the United States, there is no association between clinical benefit of cancer drugs and their prices,” says lead author, Kerstin Vokinger from the University of Zurich.
The research looked at 65 drugs in the four countries and found no significant difference in monthly treatment costs between drugs with high clinical benefit compared with low benefit. The study relied on well-established systems in the US and Europe for evaluating clinical benefit.
For example, in the treatment of prostate cancer, the drug cabazitaxel had lower clinical benefit scores than the drug abiraterone but had similar monthly costs in the US and Germany. In England and Switzerland, the less beneficial drug was even more expensive than the more effective drug arbiraterone.
“The pricing of cancer drugs is only partially justified. Drugs that are less effective should be cheaper than those with high efficacy,” Vokinger says.
Twice the price
The research also found that Americans pay twice as much for the same drug as a result of the free, unregulated market in the US. The median monthly treatment costs for cancer drugs studied were $13,179 (CHF12,723) in the US compared with $5,696 in Switzerland.
In contrast to the US, national authorities can negotiate prices directly with manufacturers in Europe but even then, prices still vary with Switzerland boasting the second-highest prices after England.
France is the only country where a correlation could be found based on one of the clinical benefit assessment systems, according to the study.
Vokinger told swissinfo.ch that prices vary across countries in part because of the different systems of analysis used. The Swiss Federal Office for Public Health (FOPH) considers both the added benefit of a drug and prices in reference countries such as Germany.
However, she notes that power dynamics also play a role. Health authorities are often under pressure to negotiate prices quickly after drugs are approved in the US, putting them in a weak negotiating position vis-à-vis manufacturers.
Calls for transparency
Study authors argue national authorities should take greater account of the clinical benefits of drugs when negotiating prices. Prioritising drugs that are more effective will help governments use resources more efficiently, Vokinger told swissinfo.ch.
The findings also reveal glaring opacity in price negotiations. Last year several governments including Switzerland backed a proposal at the World Health Organisation calling for more transparency in drug price negotiations. This struck a nerve with many big pharmaceutical companies, some of which have defended high prices arguing that price should be based on the value they bring to society not on research and development costs.
“We need evidence-based data to make conclusions about the societal value of drugs and whether a drug is worth CHF2 million,” says Vokinger. “If our healthcare system is broke, we have a real problem.”
More
More
High pharma margins squeeze health systems
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
Swiss climate activists block vehicles near Gotthard tunnel
This content was published on
Around ten climate activists briefly blocked the A2 motorway near the northern entrance of the Gotthard tunnel on Thursday.
Watches belonging to Michael Schumacher up for auction
This content was published on
Schumacher's family is auctioning off eight rare watches from his collection in Geneva. The Christie's auction will take place on Monday.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
Swiss authorities announce cost-cutting in asylum sector
This content was published on
The government notably wants to improve integration into the labour force, particularly for people with protection status S.
Various leaders confirm participation at Ukraine peace conference
This content was published on
The presidents of Poland, Finland, and Latvia and the prime ministers of Spain and Belgium will be at the Swiss-hosted talks in mid-June.
This content was published on
In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.
Rhine flooding: Swiss to invest CHF1 billion with Austria
This content was published on
As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.
Swiss government proposes CHF10 million UNRWA donation
This content was published on
After months of debate, Switzerland plans to give CHF10 million ($11 million) to the UN agency this year, rather than the CHF20 million initially foreseen.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Inside Roche: Taking on the tech sector
This content was published on
With its big bet on data and digitilisation, Roche has its eye on a new crop of specialists. Now it just needs to woo them.
Health detectives deployed in fight against coronavirus
This content was published on
To contain Covid-19, all those who have been in close contact with a contaminated person must be tracked down – a job for health detectives.
Swiss pharma giants swallow up start-ups in push for next big gene therapy
This content was published on
Swiss drug makers are increasingly relying on buying science rather than doing it themselves in the search for the next big medical breakthrough.
Swiss deal on cystic fibrosis drugs could change price negotiations
This content was published on
A deal between Swiss health authorities and Vertex brings relief to cystic fibrosis sufferers but also shows the power of patient advocacy.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.